A previous study identified that breast cancer patients with high CD8+ T-cell infiltration, especially the basal-like subtype, had higher potential benefits from immune checkpoint molecules (ICMs), such as PD-1 and CTLA4 (31). Here, CD8A is linked to breast cancer.